Condition: Oligodendroglioma · Sponsor: University Hospital Heidelberg
Oligodendrogliomas in the novel edition of the Central Nervous System (CNS) World Health Organization (WHO) classification are now molecularly defined by isocitrate dehydrogenase (IDH)1 or IDH2 mutations and 1p/19q co-deletion. The prognosis of these molecularly defined tumors is to be determined in new series since survival data from older histology-based studies and population-based registries are confounded by the inclusion of 20-70% not molecularly matching subsets. Also, the optimal treatment is a matter of ongoing investigations. An extensive, but safe surgery is associated with improved outcome as is the addition of chemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) to the partial brain radiotherapy (RT). However, the exact timing of postsurgical therapy especially for tumors of the WHO grade 2 and acknowledging some variability in grading as well as the choice of chemotherapy, temozolomide instead of PCV (CODEL: NCT00887146 randomizing CNS WHO grade 2 and 3 oligodendrogliomas to chemoradiation(CHRT)therapy with PCV or with temozolomide) or the need for primary radiotherapy RT are subjects of clinical studies (POLCA: NCT02444000 randomizing patients with newly diagnosed CNS WHO grade 3 oligodendrogliomas to standard CHRT with PCV or PCV alone). Given the young age of patients with CNS WHO grade 2 and 3 oligodendrogliomas and the relevant risk of neurocognitive, functional and quality-of-life impairment with the current aggressive standard of care t…
This description comes directly from the study's public registry record.
Wolfgang Wick, Prof. Dr. · +49 6221 56 · wolfgang.wick@med.uni-heidelberg.de
Antje Wick, PD Dr. · +49 6221 56 · antje.wick@med.uni-heidelberg.de
Always discuss trial participation with your own doctor first.
| University Hospital Heidelberg, Department of Neurooncology | Heidelberg, Baden-Wurttemberg, Germany | Recruiting |
| Charité, University Medicine Berlin, Neurosurgery | Berlin, Germany | Recruiting |
| Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic | Bochum, Germany | Recruiting |
| University Hospital Bonn, Neurology Clinic | Bonn, Germany | Recruiting |
| Chemnitz Hospital, Neurosurgery | Chemnitz, Germany | Recruiting |
| University Hospital Cologne, Neurosurgery | Cologne, Germany | Recruiting |
| University Hospital Duesseldorf, Neurooncology | Düsseldorf, Germany | Recruiting |
| University Hospital Frankfurt, Neurooncology | Frankfurt, Germany | Recruiting |
| University Hospital Göttingen, Neurosurgery | Göttingen, Germany | Recruiting |
| University Hospital Saarland, Neurosurgery | Homburg, Germany | Recruiting |
| University Hospital of Jena, Neurosurgery | Jena, Germany | Recruiting |
| University Hospital Leipzig, Radiation Therapy | Leipzig, Germany | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05331521